Servier, the manufacturer of strontium ranelate will no longer offer the drug to the UK after August. This is because the drug has limited uses and relatively few patients are on the drug.
Protelos was license in the UK for the treatment of severe osteoporosis in postmenopausal women and adult men at high risk of fracture.
The MHRA has expressed safety concerns regarding the drug’s link to cardiovascular risks. As a result, its use has been limited and the number of patients receiving the treatment has gradually decline.
https://www.gov.uk/drug-safety-update/strontium-ranelate-cardiovascular-risk
In recent times Strontium has been generally prescribed in secondary care. And we found the drug to be very useful in young patients.
Strontium ranelate supply will cease worldwide from August 2017.
Dr Mahmud and team at London Osteoporosis Clinic recommend patients to see their GP for a review of treatment options. Alternative pharmaceutical options are https://www.londonosteoporosisclinic.com/drug-info/.
Osteoporosis is a serious progressive bone condition leading to bone fractures, disability and early death. Healthcare providers often fail to appropriately assess 8 out of 10 patients after an osteoporosis fracture, leading to suboptimal treatment.
There is more information about osteoporosis, diagnosis and treatment as well as prevention at https://www.londonosteoporosisclinic.com/what-is-osteoporosis/
